Given that CD73 promotes tumor formation, invasion, and metastasis dysfunction [23,24], small-molecule inhibitors or mAb of CD73 have the potential to become essential targeting anticancer agents [25,26]. The gene discussed is NT5E; the disease is neoplasm.